Jeffrey Peppercorn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jeffrey Peppercorn has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Ann Partridge
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
1 shared publicationEmily Blood
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
1 shared publicationEric Winer
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
1 shared publicationLisa A Carey
1 shared publicationNorm Fost
Department of Pediatrics, University of Wisconsin Hospital, Madison, WI, USA
1 shared publicationPaul A Godley
Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
1 shared publication
Latest Publications
- 1 February 2008
- Published by Elsevier in The Lancet
- Vol. 371 (9611) , 527-529
The dilemma of data-safety monitoring: provision of significant new data to research participants
- 1 February 2008
- Published by Elsevier in The Lancet
- Vol. 371 (9611) , 527-529
The dilemma of data-safety monitoring: provision of significant new data to research participants
- 1 February 2008
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 8 (2) , 191-194
Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?
Evaluation of: Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient Cyp2D6 and Cyp2c19 genotypes. J. Clin. Oncol. 25, 5187-5193 (2007). Tamoxifen is one of the most commonly used treatments for breast cancer but is not effective in all patients. We review the study by Schroth and colleagues, evaluating the correlation between genotype for CYP2D6 and other enzymes involved in tamoxifen metabolism and breast cancer outcome. This study demonstrates that patients treated with tamoxifen with intermediate and poor metabolism genotypes have a higher risk of relapse, independent of other prognostic factors. Patients who were not treated with tamoxifen had no differences in outcomes based on CYP2D6 status. This study adds to the growing body of literature suggesting that genetic differences in patients can determine the effectiveness of tamoxifen and highlights the need for studies evaluating how genotype can best guide selection of endocrine therapy for breast cancer.
- 1 February 2008
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 8 (2) , 191-194
Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?
Evaluation of: Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient Cyp2D6 and Cyp2c19 genotypes. J. Clin. Oncol. 25, 5187-5193 (2007). Tamoxifen is one of the most commonly used treatments for breast cancer but is not effective in all patients. We review the study by Schroth and colleagues, evaluating the correlation between genotype for CYP2D6 and other enzymes involved in tamoxifen metabolism and breast cancer outcome. This study demonstrates that patients treated with tamoxifen with intermediate and poor metabolism genotypes have a higher risk of relapse, independent of other prognostic factors. Patients who were not treated with tamoxifen had no differences in outcomes based on CYP2D6 status. This study adds to the growing body of literature suggesting that genetic differences in patients can determine the effectiveness of tamoxifen and highlights the need for studies evaluating how genotype can best guide selection of endocrine therapy for breast cancer.
- Open Access
Association between pharmaceutical involvement and outcomes in breast cancer clinical trials
BACKGROUND.: Since 1992, pharmaceutical industry support has surpassed National Institutes of Health funding for clinical research in the United States. In this study, the authors sought to evaluate the impact of this shift in funding from public to private sponsors on the nature of published breast cancer clinical research.METHODS.: All published breast cancer clinical trials from 2003, 1998, and 1993 were reviewed from 10 select English‐language medical journals to evaluate pharmaceutical involvement over time and the association between sponsorship, trial design, and results. Clinical studies that reported disease‐specific outcomes from medical therapy for breast cancer were eligible for analysis. Pharmaceutical involvement was defined as reported pharmaceutical industry funding, provision of drug, and/or authorship for each publication.RESULTS.: In total, 140 eligible studies were identified, including 45 studies that were published in 1993, 39 studies that were published in 1998, and 56 studies that were published in 2003. Among those, 67 publications (48%) reported pharmaceutical industry involvement, 36 publications (26%) had at least ≥1 pharmaceutical industry author, And 100 publications (71%) were considered positive. Pharmaceutical involvement was identified in 44% of the studies published in 1993, in 38% of the studies published in 1998, and in 58% of the studies published in 2003. Pharmaceutical authorship was reported in 22% of the 1993 studies, in 21% of the 1998 studies, and in 34% of the 2003 studies. For studies that were published in 2003, those that reported pharmaceutical involvement were more likely to be positive (84% vs 54%; P = .02; Fisher exact test), to be single‐arm studies (66% vs 33%; P = .03), and to evaluate metastatic disease (72% vs 46%; P = .06).CONCLUSIONS.: Pharmaceutical involvement in published clinical breast cancer research may affect study design, focus, and results. Further research is warranted, including analysis of unpublished studies, to evaluate the impact of increasing pharmaceutical industry involvement on clinical research. Cancer 2007;109:. © 2007 American Cancer Society.
Open AccessAssociation between pharmaceutical involvement and outcomes in breast cancer clinical trials
BACKGROUND.: Since 1992, pharmaceutical industry support has surpassed National Institutes of Health funding for clinical research in the United States. In this study, the authors sought to evaluate the impact of this shift in funding from public to private sponsors on the nature of published breast cancer clinical research.METHODS.: All published breast cancer clinical trials from 2003, 1998, and 1993 were reviewed from 10 select English‐language medical journals to evaluate pharmaceutical involvement over time and the association between sponsorship, trial design, and results. Clinical studies that reported disease‐specific outcomes from medical therapy for breast cancer were eligible for analysis. Pharmaceutical involvement was defined as reported pharmaceutical industry funding, provision of drug, and/or authorship for each publication.RESULTS.: In total, 140 eligible studies were identified, including 45 studies that were published in 1993, 39 studies that were published in 1998, and 56 studies that were published in 2003. Among those, 67 publications (48%) reported pharmaceutical industry involvement, 36 publications (26%) had at least ≥1 pharmaceutical industry author, And 100 publications (71%) were considered positive. Pharmaceutical involvement was identified in 44% of the studies published in 1993, in 38% of the studies published in 1998, and in 58% of the studies published in 2003. Pharmaceutical authorship was reported in 22% of the 1993 studies, in 21% of the 1998 studies, and in 34% of the 2003 studies. For studies that were published in 2003, those that reported pharmaceutical involvement were more likely to be positive (84% vs 54%; P = .02; Fisher exact test), to be single‐arm studies (66% vs 33%; P = .03), and to evaluate metastatic disease (72% vs 46%; P = .06).CONCLUSIONS.: Pharmaceutical involvement in published clinical breast cancer research may affect study design, focus, and results. Further research is warranted, including analysis of unpublished studies, to evaluate the impact of increasing pharmaceutical industry involvement on clinical research. Cancer 2007;109:. © 2007 American Cancer Society.
- 1 January 2006
- Published by Springer Nature in International Journal of Pharmaceutical Medicine
- Vol. 20 (4) , 233-242
Ethical Issues in Phase I Cancer Clinical Trials
- 1 January 2006
- Published by Springer Nature in International Journal of Pharmaceutical Medicine
- Vol. 20 (4) , 233-242
Ethical Issues in Phase I Cancer Clinical Trials